Cigna (CI) saw a recent share decline despite raising its dividend and reaffirming 2026 guidance. Key developments this week: a near 2.7% intraday drop, a higher quarterly dividend, insider sales, a modest analyst price-target trim, and AM Best credit affirmation. These events create mixed signals for investors ahead of the company’s upcoming earnings.

Cigna’s shares fell after a CMS Medicare Advantage rate proposal sent insurer stocks lower. Cigna’s limited MA exposure and Evernorth diversification helped limit the hit; analysts retain constructive 12‑month targets.

Cigna's late-February gains mask deeper headwinds: weaker-than-expected 2026 guidance, Evernorth's PBM model transition, and ACA/Medicaid funding changes that pressure enrollment and margins.

Cigna (CI) posted a strong Q4 beat with EPS of $8.08, $72.5B revenue and a 3.3% dividend increase, yet its stock slipped in mid-February amid risk‑off selling tied to geopolitical headlines and lower-than-average trading volume. Analysts remain constructive with raised EPS outlooks and above‑market price targets, while competitive pressure from Amazon Pharmacy and PBM dynamics merit close monitoring.

Cigna's recent announcement of roughly 2,000 layoffs, its Q4 2025 results led by Evernorth, and a strategic shift toward a rebate-free PBM model have immediate financial and operational implications for CI stock. This article breaks down the near-term cost-savings, earnings drivers, regulatory touchpoints and what investors should watch next.

Cigna reported strong full-year 2025 results driven by Evernorth growth, raised its quarterly dividend and issued a confident 2026 outlook. While the stock saw modest post-earnings gains, sector headwinds—most notably collapsing ACA enrollment for some peers—remain a watch item for investors.